loader2
Login Open ICICI 3-in-1 Account
  • Text Size
  • Text to Speech
  • Color Contrast
  • Pause Animations

Open ICICI
3-in-1 Account

Manage your Savings, Demat and Trading Account conveniently at one place

+91

BLOG

Indian Pharma Market grew at 17.1% YoY to ₹ 25,276 crore in Sept 2026

ICICIdirect Research 12 Oct 2026 DISCLAIMER

News: As per IQVIA, Indian Pharma Market grew at 17.1% YoY to ₹ 25,276 crore in Sept 2026. On the MAT (trailing 12 months) basis, IPM witnessed a growth of 13.2% to ₹ 275,072 crore. As per data,  VMN grew 22%; Anti Diabetic posted a growth of 21%, followed by Cardiac, Derma and Pain - 20%; Neuro and Gastro -18%, Gynaec- 17% while Anti-Infectives and Respiratory segments were laggards with a growth of 9%/3% respectively. Company-wise growth numbers - Zydus- 20%, Glenmark, Emcure, Torrent, P&G Health - 19%; Sun Pharma – 18%%; Dr Reddy, Mankind - 17%, Lupin, Ipca - 16%; Cipla, Abbott, Alkem, Alembic - 15%; and Indoco, Pfizer - 5%. Acute has shown growth of 16% whereas Chronic has shown growth of 19% for the month. 

View: IPM growth has been consistently witnessing higher traction, outpacing the 7-9% growth band which was observed during FY24 and FY25. This incremental growth was mainly driven by increased patient volumes, higher offtake of high-value brands (anti-diabetic), increased penetration of players in to extra-urban areas via MR addition and continued traction from chronic therapies in general and Cardiology / Diabetology in particular. We expect domestic formulations of Indian pharma companies to remain in good stead with additional tailwinds from GLP 1 opportunities and opportunities stemming from Schedule M-driven vacuums. 

Impact: Positive

Download
ICICI Direct app

Invest, Track, and Manage your Portfolio Anytime, Anywhere

Download
ICICI Direct app

Invest, Track, and Manage your Portfolio Anytime, Anywhere